Nexalin Technology (NXL) Depreciation & Amortization (CF) (2026)
Nexalin Technology (NXL) posted Depreciation & Amortization (CF) of $2738.0 for Q2 2026, down 33.32% on a QoQ basis from $4106.0 in Q1 2026.
Powered by 
Analysis
Nexalin Technology (NXL) Depreciation & Amortization (CF) (2026) Analysis & Trends
Nexalin Technology has reported Depreciation & Amortization (CF) for 1 years, with the latest figure at $2738.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 192.30 Mn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 729.00 Mn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 355.00 Mn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 42.70 Mn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 68.20 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 123.80 Mn |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 | 2,738.00 |